Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study
Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study
复制标题
DOI：
10.1016/j.urology.2023.02.003
复制
发表时间：
2023-05-29
期刊：
影响因子：
2.1
通讯作者：
Fukuhara, Hiroshi
中科院分区：
文献类型：
--
作者：
Kinjo, Manami;Masuda, Kazuki;Fukuhara, Hiroshi
目的比较米拉贝格隆与威贝格隆治疗绝经后未经治疗的膀胱过度活动症(OAB)的疗效和安全性。患者采用分层随机分组的方法，每日服用米拉贝隆或威贝格隆50 mg，疗程12周。分别于治疗前、治疗后4周、12周进行OAB症状评分(OABSS)和生活质量指数(QOL)评定。结果213例患者随机分为米拉贝格龙组(97例)和维贝格龙组(102例)，治疗前和治疗12周后分别观察患者排尿日记和残余尿量。治疗12周后，两组患者的OABSS评分、生活质量指数、排尿次数、尿急发作次数、尿失禁次数、24小时排尿量均较治疗前有明显改善，两组改变率差异无统计学意义。术后12周，两组残余尿量差异无统计学意义。两组患者因不良反应而停药的发生率分别为6.2%和6.8%，差异无统计学意义(P>0.05)。结论米拉贝格隆50 mg和维贝格隆50 mg均能改善绝经后妇女单纯OAB的症状和排尿日记参数。泌尿外科175：67-73,2023年。©；2023爱思唯尔公司
OBJECTIVE To compare the efficacy and safety of mirabegron versus vibegron in postmenopausal women with treatment-naive overactive bladder (OAB).METHODS We conducted a prospective randomized controlled study of women with treatment-naive OAB. The patients received mirabegron or vibegron at 50 mg daily for 12 weeks by a stratified random-ized method. The OAB symptom score (OABSS) and quality of life (QOL) index were evaluated before and 4 and 12 weeks after the treatment. The patients' 3-day voiding diary and postvoided residual urine volumes were evaluated before and 12 weeks after the treatment.RESULTS Of 213 patients initially enrolled in this study, 199 patients were randomized to the mirabegron group (n = 97) or vibegron group (n = 102). Twelve weeks after the treatment, OABSS, QOL index, the numbers of micturition, urgency episodes, incontinence episodes, and voided volume per 24 hours were significantly improved compared with the baseline in both groups, and there was no significant difference in the rate of change in both groups. The postvoid residual urine vol-ume was not significantly different in the 2 groups at 12 weeks. Discontinuation because of adverse effects was observed in 6.2% of patients in the mirabegron group and 6.8% in the vibegron group, with no significant difference between 2 groups.CONCLUSION Both mirabegron at 50 mg and vibegron at 50 mg improved OAB symptoms and the parameters of voiding diary equally in postmenopausal women with treatment naive OAB. UROLOGY 175: 67-73, 2023. & COPY; 2023 Elsevier Inc.